Clinical Trials · NCT04466566

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Adrian Vella
Enrollment
21
Start date
Oct 2022
Locations
1 site, United States
Primary endpoint
Average Insulin Secretion in Response to Hyperglycemia
View Liraglutide compound reference